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Background: Cerium dioxide nanoparticles (nanoceria) are increasingly being used in a variety
of products as catalysts, coatings, and polishing agents. Furthermore, their antioxidant properties
make nanoceria potential candidates for biomedical applications. To predict and avoid toxicity, information about their biokinetics is essential. A useful tool to explore such associations
between exposure and internal target dose is physiologically based pharmacokinetic (PBPK)
modeling. The aim of this study was to test the appropriateness of our previously published
PBPK model developed for intravenous (IV) administration when applied to various sizes of
nanoceria and to exposure routes relevant for humans.
Methods: Experimental biokinetic data on nanoceria (obtained from various exposure routes,
sizes, coatings, doses, and tissues sampled) in rats were collected from the literature and also
obtained from the researchers. The PBPK model was first calibrated and validated against IV
data for 30 nm citrate coated ceria and then recalibrated for 5 nm ceria. Finally, the model was
modified and tested against inhalation, intratracheal (IT) instillation, and oral nanoceria data.
Results: The PBPK model adequately described nanoceria time courses in various tissues for
5 nm ceria given IV. The time courses of 30 nm ceria were reasonably well predicted for liver
and spleen, whereas the biokinetics in other tissues were not well captured. For the inhalation,
IT instillation, and oral exposure routes, re-optimization was difficult due to low absorption and,
hence, low and variable nanoceria tissue levels. Moreover, the nanoceria properties and exposure
conditions varied widely among the inhalation, IT instillation, and oral studies, making it difficult
to assess the importance of different factors.
Conclusion: Overall, our modeling efforts suggest that nanoceria biokinetics depend largely
on the exposure route and dose.
Keywords: biodistribution, cerium dioxide, inhalation, instillation, intravenous, oral
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The most common commercial form of cerium is cerium dioxide, also known as ceric
oxide or ceria. Nanoscale forms of ceria (nanoceria) are used in a variety of products
as catalysts, fuel additives and cells, polishing agents, and coatings.1–4 The ability of
nanoceria to react catalytically with reactive oxygen species has made it interesting for
use in biomedical applications, such as therapeutic agents in the treatment of diseases
related to oxidative stress, including obesity, wound healing, retinal degeneration, and
Alzheimer’s disease.5–10
Increased consumer and worker exposure to nanoceria combined with sparse availability and conflicting toxicological information have raised concerns for health effects
in the human population.3,11,12 Systemic uptake of nanoceria is quite low (typically ,1%

Dovepress

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 128.163.8.74 on 09-Jan-2019
For personal use only.

Carlander et al

for inhalation and even less for oral exposure), nevertheless
bioaccumulation may occur due to slow dissolution and
excretion.13–15 Acute toxicity is considered to be low; however, long-term inhalation and oral studies show that toxicity
may occur in tissues distant to the uptake site, suggesting
systemic uptake is of importance.3,16–18 For example, high
oral doses of nanoceria caused severe liver, spleen, and brain
damage in rats.17 The results of safe-by-design concepts used
in an attempt to reduce toxicity are promising. For example,
the lung inflammatory response to intratracheal (IT) instillation of nanoceria coated with amorphous silica was lower
compared to uncoated nanoceria.19
To better predict the toxic effects and toxic mechanisms
of nanomaterials, understanding their biokinetics is crucial.
Biokinetics can be elucidated by physiologically based pharmacokinetic (PBPK) modeling. The PBPK model converts
physiological and anatomical properties to mass balance equations and describes the time-dependent fate of substances in the
body, linking exposure to the internal (target) dose.20,21 By use
of experimental data from biodistribution studies, the model
can be developed, calibrated, refined, and validated.22,23 There
is a limited number of PBPK models for nanoparticles, and to
our knowledge, so far, no model for intravenous (IV) exposure
has been calibrated and validated for nanoceria.24–51
Modeling efforts have demonstrated that there are many
challenges to the development of models for nanoparticles.22,23,52
The biological activity of nanoparticles differs from their
solute and larger forms.53–59 However, these factors are not
well characterized in quantitative terms and thus not readily
implemented in PBPK models. One limiting factor in the
development of PBPK models for nanoparticles is the availability of rich in vivo data, with well-characterized properties
of nanoparticles, multiple doses, multiple tissues, and multiple

sampling times. The IV route is important as bioavailability is
100%; hence, IV studies serve as a reference when studying
biokinetics after exposure via other routes. In addition, IV dosing is the likely choice if nanoceria are to be used as therapeutic
agents, since bioavailability via other routes is low.
In this study, we applied our previously developed PBPK
model for different nanoparticles given IV to rats to nanoceria of different sizes and coatings.52 We further modified
the model to account for inhalation, IT instillation, and oral
exposures to nanoceria.

Materials and methods
Data source
Experimental data on the biodistribution of nanoceria administered to rats were collected from the literature or received
directly from authors. Data published only in graphs were
extracted using WebPlotDigitizer version 2.6. Only studies
where dose and tissue levels of nanoceria could be converted
to mass or concentration were included. Data were converted
to cerium dioxide concentration. We found eight publications
of biodistribution studies with IV exposure, reporting 21 data
sets with different nanoceria sizes (3, 5, 15, 30, 40, and
55 nm), coatings (uncoated, citrate, or EDTA-citrate), doses
(between 6 and 750 mg/kg), and dosing methods (bolus and
infusion).15,60–66 Inhalation or IT instillation were addressed in
seven publications, which included 14 data sets.13,14,18,49,53,67,68
Oral uptake was described in six publications, which included
12 data sets.14,17,53,67,69,70 The experimental studies are summarized in Tables 1–4.
Due to the limited and scattered nature of these biodistribution studies, assigning the data to calibration and validation
sets could not be randomized. Instead, the data sets for
calibration were chosen based on the following inclusion

Table 1 Summary of biodistribution studies with IV dosed Sprague Dawley rats which are used to calibrate and validate the PBPK
model for 5 nm ceria
Exposure
Calibration
Infusion (1 h)
Infusion (1 h)
Validation
Infusion (1 h)
Infusion (1 h)
Infusion (1 h)
Bolus

Size Coating
(nm)

Dose
Post-exposure sampling times
(mg/kg)

Tissues sampled

5a
5a

Citrate
Citrate

85
11

1 h, 20 h, 30 d
30 d

Bl, Br, Li, Sp
60
Bl, BM, Bo, Br, He, Ki, Li, LN, Lu, Mu, Sp, Th 61

5a
5a
5a

Citrate
Citrate
Citrate

85
85
55

0.17 h, 0.5 h, 0.75 h, 1 h, 20 h, 30 d
1 h, 20 h
30 d

3b

Citrate/EDTA 10

Bl
Bl, Br, Li, Sp
AG, Bl, BM, Bo, Br, Fa, He, Ki, Li, LN, Lu,
Mu, Sp, Th
0.08 h, 0.33 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 24 h Bl

Reference

65
63
61
62

Notes: aMeasured by TEM. bMeasured by DLS and TEM.
Abbreviations: AG, adrenal gland; Bl, blood; BM, bone marrow; Bo, bone; Br, brain; d, days; DLS, dynamic light scattering; Fa, fat; h, hours; He, heart; IV, intravenous; Ki, kidney;
Li, liver; LN, lymph node; Lu, lung; MMAD, median aerodynamic diameter; Mu, muscle; PBPK, physiologically based pharmacokinetic; Sp, spleen; Th, thymus; TEM, transmission
electron microscopy.
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Table 2 Summary of biodistribution studies with IV dosed rats which are used to calibrate and validate PBPK model for 30 nm ceria
Exposure

Sizea Coating
(nm)

Dose
Post-exposure
(mg/kg) sampling times

Tissues sampled

31

Citrate

87

24 h, 7 d, 30 d, 90 d

AG, Bl, BM, Br, Cr, CSF, Fe, He, Int, S. Dawley U+F
Ki, Li, Lu, Mu, Pe, SC, Sk, Sp, Te, Th

15

Validation
Infusion (0.5, 2.5, 30
or 7.5 h)

Citrate

1 h, 20 h

Bl, Br, Li, Sp

–

66

Infusion (1 h)

31

Citrate

50
250
750
85

S. Dawley –

65

Infusion (1 h)
Infusion (1 h)

31
31

Citrate
Citrate

85
6

S. Dawley –
S. Dawley

60
61

Bolus

28
29

Uncoated 1
Silica
1

Wistar

53
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Calibration
Infusion (1 h)

Rat
strain

Fisher

0.17 h, 0.5 h, 0.75 h, 1 h, Bl
20 h, 24 h, 7 d, 30 d, 90 d
1 h, 20 h, 30 d
Bl, Br, Li, Sp
1 h, 30 d, 90 d
AG, Bl, BM, Br, Fa, He, Ki, Li, LN,
Lu, Mu, Sk, Sp, Th
2 h, 2 d
Bl, BM, Br, Ce, Fe, He, Ki, Li, LIn,
Lu, Mu, Pl, RBC, SIn, Sk, Sp, St, Te

Excreta Reference
sampled

–

Notes: aMeasured by TEM.
Abbreviations: AG, adrenal gland; Bl, blood; BM, bone marrow; Br, brain; Ce, cecum; Cr, cranium; CSF, cerebrospinal fluid; d, days; F, feces; Fa, fat; Fe, femur; h, hours; He,
heart; Int, intestine; IV, intravenous; Ki, kidney; Li, liver; LIn, large intestine; LN, lymph node; Lu, lung; Mu, muscle; PBPK, physiologically based pharmacokinetic; Pe, pelvis; Pl,
plasma; RBC, red blood cells; SC, spinal column; SIn, small intestine; S. Dawley, Sprague Dawley; Sk, skin; Sp, spleen; St, stomach; Te, testis; Th, thymus; TEM, transmission
electron microscopy; U, urine.

criteria: 1) the total recovered mass in analyzed tissues should
be at least 25% of the injected dose, and 2) nanoceria levels
should be reported for more than four internal tissues and
include at least three time points. The remaining data sets
were used for validation.

Comparison of biodistribution data
for the non-IV exposure routes
The collected data sets for biodistribution after inhalation
exposure, IT instillation, and oral administration varied in study
design (dose, dose frequency, sampling frequency, and collected
tissues), and the nanoceria used had different properties.
Only the administered dose was given in these data
sets, the systemically absorbed fraction being unknown.
However, liver is a major target tissue for nanoceria and the
most frequently sampled internal organ in the data sets. The
nanoceria mass in liver was therefore used as a surrogate for
systemic absorption; this allowed for comparison among the
different studies. Nanoceria translocation from the lung and
gastrointestinal tract was thus calculated by dividing the mass
in liver with the IT and orally administered dose, respectively.

For inhalation, the nanoceria mass in lung was used instead
of administered dose.
Reported delivered dose and internal organ concentrations differed substantially among exposure routes. To allow
for comparisons of the biodistribution among data sets and
exposure routes, the experimental data were first normalized
by dividing the nanoceria concentration in each tissue by the
average concentration in the liver, here called the tissue:liver
concentration ratio.

PBPK model structure
Studies of nanoceria given IV to rats show, as do similar
studies with other nanoparticles, that nanoceria are captured
by phagocytic cells (PCs) in tissues belonging to the mononuclear phagocyte system (MPS), including liver, spleen, and
bone marrow.14,53,61,63 Once distributed to the MPS, nanoceria
reside there for a long time.14,15 We based the PBPK model
on the one previously developed by Carlander et al.52 The
model consists of 10 compartments: arterial blood, venous
blood, liver, spleen, lung, kidney, heart, brain, bone marrow,
and other tissues (Figure 1). Each compartment is divided

Table 3 Summary of biodistribution studies with Sprague Dawley rats IV dosed with 15 and 55 nm ceria
Exposure

Sizea
(nm)

Coating

Dose
(mg/kg)

Post-exposure sampling times

Tissues
sampled

Reference

Infusion (1 h)

15
55
15
55

Citrate
Citrate
Citrate
Citrate

70
50
70, 345
50, 100

0.17 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 20 h
0.17 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 20 h
1 hb, 30 dc
1 hd, 20 he

Bl
Bl
Bl, Br, Li, Sp
Bl, Br, Li, Sp

65

Infusion (1 h)

60

Notes: aMeasured by TEM. bSampling time for 345 mg/kg. cSampling time for 70 mg/kg. dSampling time for 100 mg/kg. eSampling time for 50 and 100 mg/kg.
Abbreviations: Bl, blood; Br, brain; d, day; h, hour; IV, intravenous; Li, liver; Sp, spleen; TEM, transmission electron microscopy.
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Table 4 Summary of inhalation, IT instillation, and oral biodistribution studies with nanoceria in rats
Exposure

Size

Coating

Inhalation

TEM 40 nm
Uncoated
MMAD 1.17 µm
TEM 5–10 nm Uncoated
MMAD 1.02 µm
TEM 40 nm
Uncoated
MMAD 1.17 µm
TEM 2–3 nm Uncoated
(pristine)

IT instillation TEM 7 nm,
DLS 13 nm

Oral

Uncoated
(aged)
Uncoated

Dose/exposure
concentration,
dose/exposure
schedule

Post-exposure
sampling times

Tissues sampled Excreta Rat
sampled strain

Reference

20 mg/m3, 6 h/d,
1, 11 and 19 d
exposures, nose only
11 mg/m3, 6 h/d,
and 20 d exposures,
nose only
25 mg/m3, 6 h/d, 5
d/w, 4 w, whole body
0.2, 0.6 mg/m3,
4 or 6 h/d, 1 d,
nose only
0.4, 0.5 mg/m3,
4 h/d, 1 d, nose only
0.2 mg

1 h, 3 da

Bl, Br, Epi, Ki, Li,
Lu, Sp, Te

–

Wistar

13

1 h, 2 db

Bl, Br, Epi, Ki, Li,
Lu, Sp, Te

–

Wistar

13

24 h,c 2 d,d 3 d,e 9 d,d
35 d,c 65 d,e 129 dc
0.25 h, 24 h, 7 d

Li, LN, Lu

–

Wistar

18

Bl, Br, GIT, He,
Ki, Li, Lu, Ofb,
Sp
Bl, Br, GIT, He,
Ki, Li, Lu, Ofb, Sp
Bl, Br, Fe, He,
Int, Ki, Li, Lu,
Mu, Sp, St, Te
Li
Bl, BM, Bo, Br, Ce,
He, Ki, Li, LIn, Lu,
Mu, Pl, RBC, SIn,
Sk, Sp, St, Te
BM, Bo, Br, Ce,
He, Ki, Li, LIn, Lu,
Mu, Pl, RBC, SIn,
Sk, Sp, St, Te
BM, Bo, Br, Ce,
He, Ki, Li, LIn, Lu,
Mu, Pl, RBC, SIn,
Sk, Sp, St, Te
Bl, Br, Fe, He,
Int, Ki, Li, Lu,
Mu, Sp, St, Te
Br, Ki, Li, Lu,
Sp, Te
Bl, Br, He, Ki,
Li, Sp
Bl, Br, He, Ki,
Li, Sp
Bl, BM, Bo, Br, Ce,
He, Ki, Li, LIn, Lu,
Mu, Pl, RBC, SIn,
Sk, Sp, St, Te
BM, Bo, Br, Ce,
He, Ki, Li, LIn, Lu,
Mu, Pl, RBC, SIn,
Sk, Sp, St, Te
BM, Bo, Br, Ce,
He, Ki, Li, LIn, Lu,
Mu, Pl, RBC, SIn,
Sk, Sp, St, Te

U+F

S.
Dawley

49

U+F

49

U+F

S.
Dawley
Wistar

–
U+F

S. Dawley 68
Wistar
14

U+F

Wistar

53

U+F

Wistar

53

U+F

Wistar

67

–

69

U+F

S.
Dawley
Wistar

U+F

Wistar

17

U+F

Wistar

14

U+F

Wistar

53

U+F

Wistar

53

0.25 h, 24 h, 7 d
6 h, 1 d, 7 d, 28 d

TEM 10 nm
TEM 40 nm
(NM-212)

Not reported 1, 3.5, 7 mg/kg
Uncoated
1 mg/kg

28 d
0.08 h,f 24 h,g 2 d,f
3 d,g 7 d,g,h 10 d,g
14 d,g 21 d,g 28 di

TEM 33 nm,
DLS 136 nm

Uncoated

1 mg/kg

0.08 h,f 24 h,g 2 d,f
3 d,g 7 d,f,g 10 d,g
14 d,g 21 d,g 28 dg,h

TEM 33 nm,
DLS 208 nm

Silica

1 mg/kg

0.08 h,f 24 h,g 2 d,f
3 d,g 7 d,f,g 10 d,g
14 d,g 21 d,g 28 dg,h

TEM 7 nm,
DLS 13 nm

Uncoated

1 mg (~5 mg/kg)

1 d, 7 d, 28 d

SEM 30 nm

Uncoated

100, 5,000 mg/kg

24 h, 7 d, 14 d

TEM 23 nm,
DLS 190 nm
TEM 24 nm,
DLS 191 nm
TEM 40 nm
(NM-212)

Uncoated

TEM 33 nm,
DLS 136 nm

Uncoated

5 mg/kg

0.08 h,j 24 h,g 3 d,g
7 dg,h

TEM 33 nm,
DLS 208 nm

Silica

5 mg/kg

0.08 h,j 24 h,g 3 d,g
7 dg,h

100, 500,
4 h, 24 h, 2 d, 3 d
1,000 mg/kg
Not reported, 30, 300, 600 mg/kg
1 d (after last dose)
99.5% pure
(daily dosing for 28 d)
Uncoated
5 mg/kg
0.08 h,h 24 h,g 3 d,g
7 dg,h

67

70

Notes: Studies in bold fulfilled the inclusion criteria for calibration. aOnly after 19 d exposures. bOnly after 20 d exposures. cTime point after start of first administration. Only lung
sampled. dTime point after start of first administration. Lung and lymph node sampled. eTime point after start of first administration. Liver, lung, and lymph node sampled. fOnly
concentration in lung and “extra pulmonary” tissues (lumping of all internal tissues) were reported for these post-exposure sampling times. gOnly samples in urine and feces. hSamples from
all tissues. iOnly concentrations in Bl, BM, Bo, Br, GIT, He, Ki, Li, Mu, Sk, Sp, Te were reported for these post-exposure sampling times. jOnly tissues samples from Bo, Lu, Mu, SIn, Sk.
Abbreviations: Bl, blood; BM, bone marrow; Bo, bone; Br, brain; Ce, cecum; d, days; DLS, dynamic light scattering; Epi, epididymis; F, feces; Fe, femur; GIT, gastrointestinal
tract; h, hours; He, heart; Int, intestine; IT, intratracheal instillation; Ki, kidney; Li, liver; LIn, large intestine; LN, lymph node; Lu, lung; MMAD, median aerodynamic diameter;
Mu, muscle; Ofb, olfactory bulb; RBC, red blood cells; S. Dawley, Sprague Dawley; SEM, scanning electron microscopy; SIn, small intestine; Sk, skin; Sp, spleen; St, stomach;
Te, testis; TEM, transmission electron microscopy; U, urine.
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Bone marrow
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Lung

PC
Heart
Urine

PC
Kidney
PC
Other tissues

Feces

PC

PC

Liver

PC

PC
PC

Spleen

Oral dose

Figure 1 Schematic illustration of the physiologically based pharmacokinetic (PBPK) model.
Notes: Black arrows indicate transport of nanoceria between subcompartments, blue and red arrows represent systemic circulation, green arrows indicate uptake into
the circulatory system, and dashed arrows indicate excretion. The blue area is venous blood, and the red area is arterial blood. Green boxes correspond to exposure via
inhalation/intratracheal instillation, and intravenous and oral administration. The grey box represents tissue. White boxes with the text PC symbolize phagocytic cells in tissue.
Orange boxes indicate clearance of nanoceria to mucus, urine, and feces.

into three sub compartments: 1) blood in tissue, 2) tissue, and
3) PCs in the tissue, with venous and arterial blood described
by two subcompartments: blood and PCs.
The PCs are described by a particle-dependent uptake
rate constant (Ksab0 for spleen and Kab0 for all other tissues),
an exocytosis rate constant (Kde), and a maximum uptake
capacity (Mcap). With one exception (Ksab0), all PCs are
assumed to have the same properties (ie, same Kab0 and Mcap),
and only their numbers (a particle-independent parameter)
differ among compartments. The model includes flow and
diffusion-limited processes from blood to tissues described
by three permeability coefficients (Xfast for liver, spleen, and
bone marrow; Xbrain for the blood–brain barrier; and Xrest for
other tissues). Partitioning between blood and other tissues
is expressed by a partition coefficient (P). Excretion occurs
from the liver and kidney and is accounted for by clearance
rate constants (CLf and CLu, respectively).
International Journal of Nanomedicine 2018:13

Systemic uptake after inhalation, IT instillation, and oral
exposure is addressed by adding a first-order absorption compartment to the PBPK model. The absorption rate constant
(a route- and particle-dependent parameter) was obtained
by best fit to each data set. Clearances from the lungs via
the mucociliary escalator and from the gastrointestinal tract
to feces are also described by first-order kinetics and were
obtained by best fit to the respective data sets. Dissolution
of nanoceria has been reported but experimental data useful
for modeling are lacking so far.71 For this reason, dissolution
is not included in the model.

Model calibration
The model was parameterized by best fit against experimental tissue concentrations of nanoceria given IV to rats.
All physiological (nanoparticle independent) parameters
of the model were kept the same as previously reported by
submit your manuscript | www.dovepress.com
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Carlander et al (Table S1), except for scaling to body weight
in the individual experiments.52 The fitted (nanoparticledependent) parameters were CLf, CLu, kab0, ksab0, kde, P, Mcap,
Xbrain, Xrest, and Xfast.
As size has been reported to influence the biokinetics
of nanoparticles, the model was fitted against 5 and 30 nm
experimental IV data separately.15,60,61 Excretion data for
nanoceria have only been reported for 30 nm particles,
where the amount of nanoceria recovered in feces and
urine was reported to be ,0.5% and 0.01% of the dose,
respectively.14,15 The clearance rate constants for urine and
feces were estimated during the calibration of the PBPK
model for 30 nm ceria and next used as fixed values in the
calibration of 5 nm ceria.
For calibration of the model for 5 nm ceria, we used two
sets of experimental data reported by Yokel et al (85 mg/kg,
1 h infusion, and 11 mg/kg, 1 h infusion) (Table 1).60,61 Both
the data sets cover three sampling times (1 h, 20 h, and 30 d
post-infusion) and report concentrations for all tissues defined
in our PBPK model. Calibration of the model for 30 nm ceria
was carried out using the richest available data set (number of
tissues collected, number of sampling times, and time span)
(87 mg/kg, 1 h infusion) (Table 2).15 This data set covers four
sampling times and cerium concentrations in all tissues in
our model as well as in urine and feces.
Regarding inhalation, IT instillation, and oral exposure
studies, only one study for inhalation, one for IT instillation,
and three for the oral route fulfilled the calibration criteria
(Table 4). The studies that did not fulfill the calibration
criteria were used to calculate liver:dose ratios for comparison among exposure routes. The calibration involved
fitting each data set by changing nanoparticle-dependent
parameters, the absorption rate constant (all three routes),
the mucociliary clearance rate constant (inhalation and IT
instillation), and the gastrointestinal clearance rate constant
(oral route).
In the calibration using inhalation, IT instillation, and
ingestion data, we departed from the initial calibration with
5 and 30 nm IV data and added two route-dependent rate
constants, for absorption (all three routes) and clearance
(mucociliary for inhalation and IT instillation, gastrointestinal for the oral route). We first tried to achieve calibration
by fitting all nanoparticle-dependent parameters. However,
no results could be obtained due to the high number of
parameters combined with relatively few data points and
widely disparate experimental data. In a second attempt, we
considered the parameters from the IV calibration and fitted
the route-dependent parameters only.
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Model validation
The model was validated with additional independent biodistribution studies that used 5 and 30 nm, or similarly sized,
ceria. In addition, as proposed by the WHO, the validation
was considered adequate if the simulated values were within
a factor of two of the measured mean values.21
Four IV data sets were used for the validation of our
PBPK model for 5 nm ceria (Table 1),61–63,65 and for the 30 nm
PBPK model, five IV data sets (Table 2)53,60,61,65 were used.
The data sets cover doses of 1–750 mg/kg, infusion durations between 0 and 7.5 h, and post-dosing sampling up to
90 days. The nanoceria were either uncoated or coated with
citrate, citrate/EDTA, or silica.

Sensitivity analysis
Local sensitivity analyses were carried out to identify the
most influential model parameters. Normalized sensitivity
coefficients were calculated by dividing the percent change in
the area under the concentration–time curve in tissues (blood,
liver, spleen, brain, and PCs) by the percent change in different model parameters, as described by Carlander et al.52

Modeling software and algorithms
Computer simulations were carried out with acslX Libero™
version 3.0.2.1 using the Gear algorithm or Berkeley
Madonna™ version 8.3.18 using the Runge-Kutta (4th-order)
method. AcslX Libero with the Nedler Mead method was
used for optimization.
The overall goodness of fit between the simulated and
experimental data was evaluated using linear regression
in GraphPad Prism 6 (GraphPad Software, Inc., La Jolla,
CA, USA).

Results
IV exposure – 5 nm ceria
As shown in Figure 2, the PBPK model adequately describes
the measured concentration of 5 nm ceria in liver, brain, and
bone marrow (less than twofold differences) and in blood,
spleen, lung, kidney, and heart reasonably well (less than
10-fold difference). Furthermore, the simulated values correlate well with the experimental data reported by Yokel et al
in 2013 (Figure S1A) and correlate reasonably well with
those reported by Yokel et al in 2014 (Figure S1B).60,61 The
overall coefficient of determination (R2) for both the data
sets is 0.91 (Figure 2).
Four independent data sets were used to validate the
PBPK model for 5 nm ceria. In three of the data sets, the
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Figure 2 Physiologically based pharmacokinetic (PBPK) model calibration of 5 nm ceria administered intravenously to rats.
Notes: (A and B) Simulated (solid curves) and experimentally observed concentrations (circles) in tissues of rats at various time points, following 1 h intravenous (IV)
infusion of 85 mg/kg body weight. Data from Yokel et al.60 (C) Simulated and experimentally observed concentrations in tissues of rats, 30 days after a 1 h infusion of 11
mg/kg body weight. Error bars represent standard deviation for experimental observed data. Data from Yokel et al.61 (D) Comparison of logs of simulated and observed mean
concentration in tissues. The line of unity (solid) represents a perfect match, and the regression line (R2, dashed) describes the outcome. Data from Yokel et al.60,61

properties were identical to those in the calibration data
sets, whereas in the fourth, the size (3 nm instead of 5 nm)
and coating (citrate/EDTA instead of citrate only) differed
slightly. The simulations indicate differences in time courses
in blood between these two types of nanoceria. Thus, for
the 5 nm ceria, the model predicts well the most observed
concentrations in tissues, whereas for the 3 nm ceria, it
underpredicts the concentration in blood at every time
point, suggesting dependence on size and coating (Figures 3
and S2). This suggests that EDTA/citrate coating prolongs
the circulation time in blood, a conclusion also drawn by
Heckman et al.62
The sensitivity analysis showed that the concentrations in
the different compartments are influenced by physiologicaland nanoparticle-dependent parameters and dose and are
time dependent (Figure 4 and Tables S2–S7, sensitivity
coefficients are shown for two time points only for each dose
set). The most influential nanoparticle-dependent parameters
are kab0, ksab0, Mcap, P, Xbrain, and Xrest, as described further
in the “Discussion” section (Figure 4). As a consequence

International Journal of Nanomedicine 2018:13

of nonlinear kinetics in the model (saturation of PCs), the
concentration in tissues does not increase in proportion to
dose as dose increases from 11 to 85 mg/kg. This nonlinearity
is seen as sensitivity coefficients that change with dose
(Figure 5). For most tissues, the sensitivity coefficients generally increase with dose rate. For liver, the trend is opposite
with decreasing sensitivity coefficients for all examined
nanoparticles (Figure 5C).

IV exposure – 30 nm ceria
The model describes the experimental data for 30 nm ceria
fairly well with a reasonable correlation between simulated
and measured values (R2 =0.82, Figure 6). In particular,
the time courses in liver and bone marrow are adequately
captured with less than twofold difference between measured
and simulated values. However, the increases in concentration observed after 90 days compared to 30 days after dosing
in various tissues (blood, brain, heart, lung, and spleen) are
not well captured, that is, the model overestimates at 30 days
but underestimates at 90 days (Figure 6).
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Figure 3 Validation of the physiologically based pharmacokinetic (PBPK) model against independent data sets with 5 nm ceria administered intravenously into rats.
Notes: (A and B) Simulated (solid curves) and observed (symbols) time courses of the concentration of 5 nm ceria in different tissues following intravenous infusion in rats
from different studies (A, data from Dan et al,65 B, data from Hardas et al63). (C) Simulated (grey columns) and observed (black columns) concentrations of 5 nm ceria in
different tissues following intravenous infusion in rats. Data from Yokel et al.61 (D) Comparison of logs of simulated and observed mean concentration in different tissues. The
line of unity (solid) represents a perfect match, and the regression line (R2, dashed) describes the outcome. Data from Yokel et al,61 Dan et al,65 and Hardas et al.63

As expected, the nanoparticle-dependent parameters
obtained for 30 nm ceria deviate from those obtained for 5 nm
ceria (Table 5). Four of the fitted nanoparticle-dependent
parameters (kab0, kde, Mcap, and Xfast) are similar, that is, within
a factor of 2. The remaining four parameters differ more, thus,
the uptake rate constant for PCs in spleen (ksab0) is 22-fold
lower; the partition coefficient between blood and tissues (P)
is fivefold lower; the coefficient of permeability from blood
to lung, kidney, heart, and carcass (Xrest) is eightfold lower;
and the coefficient of permeability from blood to brain (Xbrain)
is 242-fold lower for the 30 nm compared to 5 nm ceria.
The validation of the model against independent data
from 30 nm ceria show poor predictions for most tissues
(Figures 7 and S3–S10). The predictions are somewhat better
for liver and spleen, compared to other tissues. Half of the
predictions are within twofold of the experimental values.
The sensitivity analysis for the 30 nm ceria shows similar
pattern as for 5 nm but with fewer highly sensitive parameters (Figure 4 and Tables S2–S7). The most influential
nanoparticle-dependent parameters are kab0, ksab0, Mcap, P, and
Xrest. A change in maximum uptake capacity of PCs has less
2638
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influence on the sensitivity coefficient in the 30 nm model
than in the 5 nm model (Figure 4). Similar to the 5 nm PBPK
model, the 30 nm PBPK model suggests nonlinear (saturated)
biokinetics for nanoceria.

IV exposure – other sizes
It was not possible to calibrate the model for 15 and 55 nm
ceria due to the limited and scattered experimental data. We
therefore compared these two data sets to predictions based
on the calibrations obtained with the 5 and 30 nm data. For
both the data sets, the 5 nm provides better predictions than
the 30 nm calibration. A closer look at the simulations reveals
that the predictions for liver and spleen are reasonable,
whereas those for blood and brain are poorer. For the 15 nm
ceria, all liver and spleen values are within twofold difference, whereas for the 55 nm ceria, 80% are within fivefold
and none differ more than 10-fold (Figures S11 and S12).

Inhalation, IT instillation, and oral exposure
The compilation of data from inhalation, IT instillation, and
oral biodistribution studies underscores that the systemic
International Journal of Nanomedicine 2018:13
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uptake via these routes is limited, in agreement with conclusions previously reached by others (Figure 8).16 Less than
1% (on mass basis) of the administered dose was distributed
from lung to liver, and after oral gavage, the uptake to liver
was ,0.001%.
As systemic bioavailability differs among exposure
routes, we normalized the time courses of concentration in
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tissues to that in liver. A comparison of the time courses to the
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suggest several orders of magnitude of differences, between
and among the IV, inhalation, IT instillation, and oral routes
(Figures S13–S15). The time courses of the tissue:liver concentration ratios differ not only among exposure routes and
studies but also between tissues (Figures S13–S15).
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In spite of differences in size and coatings, the time
courses of the ratios after IV administration differed distinctly
from the ratios for other exposure routes, illustrated, for
example, by the clearly lower blood:liver concentration ratios
and the apparently higher spleen:liver concentration ratios
(Figures S13–S15). Noticeably and expected, the concentration in brain was substantially lower than in liver after IV
administration (3–5 orders of magnitude) and IT instillation
(2–4 orders of magnitude) compared to inhalation exposure
(0–2 order of magnitude), suggesting uptake via olfactory
nerves (Figure S15). This contrasts to the distribution after
2640
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oral dosing where, with few exceptions, the concentrations
in brain are in the same range as, or up to 1 order of magnitude lower than, in the liver. Finally, this suggests that the
exposure route has a large influence on the biokinetics.
The first calibration efforts with inhalation, IT instillation,
and oral data were unsuccessful, in that the model parameters
could not be estimated. In a second attempt, calibrations
were performed by adjusting the route-specific parameters
only and keeping all other model parameters from the 5 and
30 nm calibrations. With the second approach, the calibration was still unsuccessful for data set 1 from Li et al.49
International Journal of Nanomedicine 2018:13
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Unit

30 nm

CLf
CLu
kde
kab0
ksab0
Mcap
P
Xbrain
Xfast
Xrest

mL/h
mL/h
1/h
1/h
1/h
μg
Unitless
Unitless
Unitless
Unitless

5 nm

Mean

SD

Mean

SD

3.92×10-2
7.15×10-5
2.88×10-3
2.68
1.69×10-1
3.98×10-5
8.85×10-2
2.90×10-8
1.00
1.86×10-4

7.25×10-5
1.41×10-7
6.76×10-6
3.66×10-3
3.93×10-2
8.28×10-8
1.67×10-4
3.72×10-11
2.02×10-3
2.60×10-7

a

a

a

a

1.42×10-3
5.13
3.76
3.43×10-5
0.40
7.02×10-6
0.59
1.51×10-3

2.29×10-6
2.37×10-3
1.06×10-2
7.22×10-8
9.23×10-4
8.33×10-9
5.22×10-3
2.91×10-6

Notes: aFixed value, same as for 30 nm ceria.
Abbrevations: CLf, clearance rate constant to feces; CLu, clearance rate constant
to urine; kab0, uptake rate constant by phagocytic cells; ksab0, uptake rate constant
by phagocytic cells in spleen; kde, exocytosis rate constant from phagocytic cells;
Mcap, maximum uptake capacity per phagocytic cell; P, partition coefficient between
blood and tissue; Xfast, coefficient of permeability from blood to liver, spleen, and
bone marrow; Xrest, coefficient of permeability from blood to lung, kidney, heart, and
carcass; Xbrain, coefficient of permeability from blood to brain.

No calibration of the Kumari et al study was carried out
as these data were considered uncertain due to the small
amounts recovered in feces and analyzed organs, apparently ,10% of the administered dose (Figure S16).70 With
few exceptions, poor fits were achieved for the remaining
data sets (Figures S17–S23).17,49,67,69,70
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Table 5 Nanoparticle-dependent parameters of 5 and 30 nm
ceria physiologically based pharmacokinetic (PBPK) model
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Figure 8 Uptake ratio of nanoceria to liver from different exposure routes.
Notes: Translocation of nanoceria from lung and gastrointestinal tract was
calculated by dividing the cerium mass in liver with the administered dose, expressed
as mass, that is, the uptake ratio. For inhalation, the cerium lung burden was used as
the dose. For intravenous (IV) administration, the uptake ratio was calculated as the
mass in liver divided by the administered dose. The symbols represent different data
sets, and the colors represent different organs.

Discussion
The PBPK model described herein is the first to describe
the biokinetics of nanoceria injected IV in rats. In line with
previous studies, our simulations give additional support
that both properties of nanoparticles (size and coating) and
exposure conditions (dose and route) affect the biokinetics
of nanoceria.53,60 It should be noted that there are data available on experimental biokinetics of nanoceria in mice.72–74
However, rats and mice differ substantially, especially with
respect to the anatomy of the spleen and the properties of the
MPS, which requires modification of the model.75–77
In a unique attempt to compare different exposure routes
using PBPK modeling, the model structure was modified to
include inhalation, instillation, and oral administration. However, modeling of these routes was difficult, and the results
were inconclusive. We did not include intraperitoneal exposure as this route is not relevant for environmental exposure
or pharmacological treatment. Moreover, when we carried
out a literature search on IP administration, we did not find
any suitable biodistribution data for PBPK modeling.
The model adequately predicts the biokinetics of 5 nm
ceria with citrate coating given IV to rats. The model is less
successful in capturing the kinetics of other sizes of nanoceria, which partly can be explained by the larger spread in
properties among these particles. Size-dependent uptake of
nanoparticles in PCs has been reported by several research
groups, and the optimum uptake by cells seems to occur for
sizes around 40–60 nm.78,79 However, several other factors
may also affect the uptake and excretion, such as cell type,
nanoparticle–membrane binding energy, nanoparticle curvature, and corona composition.80–83 In our simulations, some
of the fitted parameters differed between 5 and 30 nm ceria
submit your manuscript | www.dovepress.com
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suggesting size dependencies, whereas other parameters were
similar for the two nanoceria sizes. Overall, our modeling
results point to dependence not only on size but also on
coating, dose, and exposure route on the biokinetics.
Coating is a known modifying factor of biokinetics
for nanoparticles, including nanoceria.53,58,62 According to
Heckman et al, the clearance of nanoceria from blood is
reduced when EDTA is added to the citrate coating.62 Our
model is well in line with this finding as our model, calibrated
with citrate-coated 5 nm ceria, predicts a faster clearance than
observed in experimental data with citrate/EDTA-coated
3 nm ceria.62 Heckman et al argued that the prolonged blood
circulation time observed for citrate/EDTA-coated nanoceria
compared to citrate-coated nanoceria may be explained by
fewer adsorbed proteins, resulting in reduced recognition and
uptake by the mononuclear phagocytic system.62 Similarly,
Konduru et al proposed that the alteration in biodistribution patterns between uncoated and silica-coated nanoceria
correlates with differences in the corona composition.53
Our PBPK model includes saturable uptake of nanoceria
in PCs as a major feature. At sufficiently high doses, tissue
levels will be less than proportional to dose as the PCs
approach saturation. Moreover, PCs are unevenly distributed
among tissues and permeability into tissues varies, as high,
medium, or low (Xbrain, Xfast, and Xrest). Therefore, the nanoceria distribution pattern will change as the dose increases.
To develop reliable and validated PBPK models, one would
need to validate them against low (non-saturating) as well
as high (saturating) doses. Unfortunately, nearly all experimental studies that could be used for modeling used a single
dose only, or a very narrow dose span (Tables 1–4).
Our model was not designed to, and cannot, account for
the peculiar biokinetic behavior seen in one of Yokel et al
studies, where the concentration increased up to three orders
of magnitude in various tissues between 1 and 3 months
after IV infusion of 30 nm ceria (Figure 6).15 One possible
explanation might be the dissolution of nanoceria in the liver
and subsequent release of cerium ion, resulting in increased
cerium in the blood and redistribution to the spleen.71,84 On the
other hand, the observed biokinetic pattern is not consistent
with that reported for cerium ion.14 If this peculiar increase
is indeed a true biokinetic phenomenon, better understanding
of the underlying physical or physiological mechanisms is
needed in order to further develop the PBPK model. In addition, improved quantitative analytical methods that are able
to distinguish between primary and secondary cerium oxide
nanoparticles and cerium ions would be needed.
When comparing the experimental data for different
exposure routes, it quickly became apparent that the present
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PBPK model is unable to describe the biokinetics for the
non-IV routes. This was later confirmed during our modeling
efforts. However, our comparison of the experimental data for
IV, inhalation, instillation, and oral exposure suggests that the
tissue distribution pattern is a result of the need for nanoceria
to cross epithelial barriers before reaching the systemic circulation (see Figures S13–S15 for time course plots of tissue:liver
concentration ratios for the different exposure routes). Modification of biodistribution as a result of exposure route has also
been demonstrated for other types of nanoparticles such as
gold.85,86 These pattern changes may be due to a “true” route
dependency, but may also reflect differences in nanoparticle
property, dose, tissue sampling techniques, sample treatment,
analytical method, and so on among the studies. The underlying mechanisms are unclear; however, modified protein binding has been suggested as a likely factor.86 Additional studies
are needed to understand the possible route dependency and
to rule out other experiment-related factors.
Development, calibration, and validation of PBPK models
for nanoparticles require reliable and relevant experimental
data that provide information about properties of nanoparticles as well as quantities in several tissues at multiple time
points over extended periods. Among all published reports
on nanoceria, only a few data sets comprised this type of
information. Small sample size in combination with high
intra- and inter-individual variability and method error are
other complication factors for modeling as these lower the
confidence in the parameter estimates as well as the model
structure. An additional problem with the non-IV exposure
routes is that absorption is generally low, resulting in very
low tissue levels, sometimes below the detection limit and/or
not different from background.
In the data sets provided by Yokel et al, we had access
to raw data, and hence individual data on body weight and
tissue weights could be used in the model.15,60,61,63,65,66 Information for the other data sets are more uncertain as they
were reported as mean values. The latter situation typically
reflects how data are reported in published biodistribution
studies where individual data points are rarely provided.
More frequent reporting of individual data would be helpful
to improve model development and to facilitate discrimination between variability and uncertainty.
Due to lack of quantitative physiological knowledge,
several of the PBPK parameters had to be fitted to experimental data. Such approaches may result in over parameterization, especially if the experimental data are limited to a few
tissues and time points. In this study, 10 parameters were optimized and 156 data points were used to calibrate the model.
Noteworthily, the number of data points were well above
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the number of parameters optimized which reduces the risk
for over fitting. In addition, the model has successfully been
used to describe the biokinetics of other nanoparticles (titanium dioxide, gold, and polyethylene-coated and -uncoated
polyacryl amide) administered IV.38,52
A parameter with a high sensitivity coefficient means that
a small change in this parameter will have a high impact on
the model output. Reliable experimental data on these parameters are hence critical. On the other hand, a parameter with
very low sensitivity can have a range of values with negligible
impact on the output. Model estimates of such parameters are
thus more uncertain. Overall, the sensitivity analysis showed
time, dose, and size dependencies (Figure 4, Tables S2–S7).
The model parameters were generally more sensitive for the
5 nm than 30 nm ceria, and in addition, the sensitivity of the
parameters increased with dose. The dose-dependent increase
in sensitivity can be explained by increased nanoceria burden
in the PCs, expressed as higher sensitivity coefficients for
such parameters as the maximum uptake capacity per PC
(Mcap), number of PCs per gram liver (ncap in liver), and liver
fraction of body weight (kwl) (Tables S2–S7).
Experimental values for physiologically based parameters
can be found in the literature, and many of them can also be
readily measured.87,88 However, reliable data on, for example,
residual amount of blood in tissues and number of PCs in
tissues are sparse. Relevant and reliable experimental data
on nanoparticle-dependent parameters are more difficult to
find. Methods, primarily in vitro, are under development, but
the result will depend on the properties of the nanoparticles
and the test method used.46,89–91 Correlations between in vitro
and in vivo results need to be established to make route-toroute extrapolations.92 Consequently, it is difficult, at least
so far, to predict how properties of nanoparticles may affect
the parameters of the PBPK model.
The biological environments in the gastrointestinal tract
and the lungs differ from that in blood, and this may affect
the behavior of the nanoparticles with respect to processes
such as agglomeration, corona formation, and nanoparticle
dissolution.57,93–95 These processes depend not only on the
environment but also on the properties of nanoparticles and
contribute to changes in the biodistribution pattern.54,81,96
There are also indications that the processes are dynamic and
change over time.54,97,98 Hence, an obvious next step would
be to examine if introduction of these processes in the PBPK
model improves the predictions. To our knowledge, there is
no PBPK model for nanoparticles with physically relevant
descriptions of agglomeration, corona formation, and dissolution, although dissolution has been empirically implemented in PBPK models for silver and zinc.35,45 A limiting
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factor is that the three processes have so far not been well
characterized in quantitative terms, and consequently, they
cannot yet be used in PBPK modeling.54
Our model has a simplified structure that describes
the deposition and transport processes in the lung and
gastrointestinal tract. Research groups have shown that a
more complex model structure for deposition and clearance in the respiratory system via mucociliary clearance to
pharynx and uptake to brain via olfactory and trigeminal
nerves is more adequate to predict the deposition of inhaled
nanoparticles.47,49 Systemic uptake of nanoparticles via the
lymphatic system and subsequent distribution to tissues has
been demonstrated but so far not incorporated in any PBPK
model for nanoparticles.99,100 This can be explained by the
challenge in visualization and sampling of lymph nodes
and the small amounts of nanoparticles therein; thus, the
observations are qualitative rather than quantitative. Even
if incorporated, the model would still not be able to explain
the route-dependent biodistribution patterns.
Our study illustrates well the usefulness of PBPK modeling to better understand the biokinetics of nanoparticles.
First, PBPK modeling can be used to challenge or generate
hypotheses. Thus, the PBPK model described herein supports
the hypothesis that coating and size influence biokinetics.
Second, PBPK models can be used to identify knowledge
gaps. In this study, we identified the need to update future
models with mechanistic understanding of exposure route
dependencies and nanoparticle interactions with body fluids
such as corona formation, agglomeration, and dissolution.
Third, PBPK models may be used to improve the design of
experimental studies. Our modeling efforts suggest dose- and
route-dependent biokinetics of nanoceria. Hopefully this will
be taken into consideration when future biodistribution studies are designed. Fourth, PBPK models can be used to predict
the biokinetics and tissue doses for new exposure scenarios
without need for new experiments. This is particularly important in risk assessment of nanoparticles when there seems to
be dose- or route-dependent biokinetics.

Conclusion
The PBPK model could adequately describe and predict
the biokinetics for 5 nm ceria with citrate coating given
IV but less well so for other sizes. For non-IV exposure
routes, calibration was difficult due to low absorption, few
samples, widely disparate data, and concentrations below
or close to the detection limit. However, the tissue time
courses seemed to differ from those in the IV experiments
and had shapes that were difficult to reproduce with the
PBPK model. Overall, our modeling results suggest that the
submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

2643

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 128.163.8.74 on 09-Jan-2019
For personal use only.

Carlander et al

biokinetics of nanoceria depend not only on the properties
of nanoparticles (size and coating) but also, and even more
so, on the exposure conditions (route and dose). Inclusion of
physically and physiologically adequate descriptions of lung
deposition, agglomeration, corona formation, and dissolution
is needed. This requires improved mechanistic understanding
and targeted experimental studies.
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